Leopold Bertea joins Immunicum

Friday 13 May 2022
Immunicum AB
Appointee name
Leopold Bertea


Leopold Bertea, a cell and gene therapy expert, has joined Immunicum AB as chief technology officer to help build a manufacturing infrastructure for the company’s lead cell-based cancer vaccine. Dr Bertea previously worked at Cellectis SA as head of technical operations Europe and was a member of the company’s executive committee. He has also held senior positions at Novartis and LFB Biotechnologies SAS.

Immunicum announced the appointment on 5 May 2022.

Copyright 2022 Evernow Publishing Ltd